Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Context Therapeutics’ Q3 2025 earnings at ($0.05) EPS and Q4 2025 earnings at ($0.05) EPS. […]
HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Context Therapeutics’ Q3 2025 earnings at ($0.05) EPS and Q4 2025 earnings at ($0.05) EPS. […]
